Shamburg News · 8-K filed Oct 5, 2026, 8:08 AM EDT

Benitec Biopharma Provides BB-301 Pivotal Study Update After FDA Type C Meeting Feedback

BNTC · Benitec Biopharma Inc.

  • Reg FD disclosure
  • Materiality: medium

Benitec Biopharma Inc. announced on October 5, 2026 that it received formal feedback from the FDA following the Type C meeting held in the third quarter of 2026. The FDA requested additional available data, including data from the Company-sponsored OPMD Natural History Study, while discussions on an open-label, single-arm pivotal study for BB-301 continue. The Company expects to confirm the final pivotal study design in 1Q 2027 and remains on track to begin enrollment in mid-2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-413177.

Written from the filing by Shamburg Markets. Figures are as reported by the company.